NEOG 10-Q Quarterly Report Feb. 28, 2022

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller Reporting Company

Emerging growth company

NEOGEN CORP

10-Ks and 10-Qs

10-Q	Quarter ended Aug. 31, 2025
10-K	Fiscal year ended May 31, 2025
10-Q	Quarter ended Feb. 28, 2025
10-Q	Quarter ended Nov. 30, 2024
10-Q	Quarter ended Aug. 31, 2024
10-K	Fiscal year ended May 31, 2024
10-Q	Quarter ended Feb. 29, 2024
10-Q	Quarter ended Nov. 30, 2023
10-Q	Quarter ended Aug. 31, 2023
10-K	Fiscal year ended May 31, 2023
10-Q	Quarter ended Feb. 28, 2023
10-Q	Quarter ended Nov. 30, 2022
10-Q	Quarter ended Aug. 31, 2022
10-K	Fiscal year ended May 31, 2022
10-Q	Quarter ended Feb. 28, 2022
10-Q	Quarter ended Nov. 30, 2021
10-Q	Quarter ended Aug. 31, 2021
10-K	Fiscal year ended May 31, 2021
10-Q	Quarter ended Feb. 28, 2021
10-Q	Quarter ended Nov. 30, 2020
10-Q	Quarter ended Aug. 31, 2020
10-K	Fiscal year ended May 31, 2020
10-Q	Quarter ended Feb. 29, 2020
10-Q	Quarter ended Nov. 30, 2019
10-Q	Quarter ended Aug. 31, 2019
10-K	Fiscal year ended May 31, 2019
10-Q	Quarter ended Feb. 28, 2019
10-Q	Quarter ended Nov. 30, 2018
10-Q	Quarter ended Aug. 31, 2018
10-K	Fiscal year ended May 31, 2018
10-Q	Quarter ended Feb. 28, 2018
10-Q	Quarter ended Nov. 30, 2017
10-Q	Quarter ended Aug. 31, 2017
10-K	Fiscal year ended May 31, 2017
10-Q	Quarter ended Feb. 28, 2017
10-Q	Quarter ended Nov. 30, 2016
10-Q	Quarter ended Aug. 31, 2016
10-K	Fiscal year ended May 31, 2016
10-Q	Quarter ended Feb. 29, 2016
10-Q	Quarter ended Nov. 30, 2015
10-Q	Quarter ended Aug. 31, 2015
10-K	Fiscal year ended May 31, 2015
10-Q	Quarter ended Feb. 28, 2015
10-Q	Quarter ended Nov. 30, 2014
10-Q	Quarter ended Aug. 31, 2014
10-K	Fiscal year ended May 31, 2014
10-Q	Quarter ended Feb. 28, 2014
10-Q	Quarter ended Nov. 30, 2013
10-Q	Quarter ended Aug. 31, 2013
10-K	Fiscal year ended May 31, 2013
10-Q	Quarter ended Feb. 28, 2013
10-Q	Quarter ended Nov. 30, 2012
10-Q	Quarter ended Aug. 31, 2012
10-K	Fiscal year ended May 31, 2012
10-Q	Quarter ended Feb. 29, 2012
10-Q	Quarter ended Nov. 30, 2011
10-Q	Quarter ended Aug. 31, 2011
10-K	Fiscal year ended May 31, 2011
10-Q	Quarter ended Feb. 28, 2011
10-Q	Quarter ended Nov. 30, 2010
10-Q	Quarter ended Aug. 31, 2010
10-K	Fiscal year ended May 31, 2010
10-Q	Quarter ended Feb. 28, 2010
10-Q	Quarter ended Nov. 30, 2009

PROXIES

DEF 14A	Filed on Sept. 12, 2025
DEF 14A	Filed on Oct. 24, 2024
DEF 14A	Filed on Sept. 13, 2024
DEF 14A	Filed on Oct. 25, 2023
DEF 14A	Filed on Sept. 18, 2023
DEF 14A	Filed on Oct. 6, 2022
DEF 14A	Filed on Aug. 30, 2022
DEF 14A	Filed on Aug. 31, 2021
DEF 14A	Filed on Aug. 31, 2020
DEF 14A	Filed on Aug. 27, 2019
DEF 14A	Filed on Aug. 28, 2018
DEF 14A	Filed on Aug. 30, 2017
DEF 14A	Filed on Aug. 31, 2016
DEF 14A	Filed on Aug. 28, 2015
DEF 14A	Filed on Aug. 29, 2014
DEF 14A	Filed on Aug. 30, 2013
DEF 14A	Filed on Aug. 31, 2012
DEF 14A	Filed on Sept. 1, 2011
DEF 14A	Filed on Sept. 1, 2010
DEF 14A	Filed on None

10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 v

FORM

10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 28, 2022 .

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission file number

0-17988

Neogen Corporation

(Exact name of registrant as specified in its charter)


Michigan		38-2367843
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

620 Lesher Place

Lansing ,

Michig an

48912

(Address of principal executive offices, including zip code)

( 517 )

372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:


Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.16 par value per share	NEOG	NASDAQ Global Select Market

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act): YES ☐ NO ☒

As of February 28, 2022 there were 107,818,159 shares of Common Stock outstanding.

Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS


		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Interim Consolidated Financial Statements (unaudited)		2

	Consolidated Balance Sheets – February 28, 2022 and May 31, 2021		2

	Consolidated Statements of Income – Three and nine months ended February 28, 2022 and 2021		3

	Consolidated Statements of Comprehensive Income – Three and nine months ended February 28, 2022 and 2021		4

	Consolidated Statements of Equity – Three and nine months ended February 28, 2022 and 2021		5

	Consolidated Statements of Cash Flows – Nine months ended February 28, 2022 and 2021		6

	Notes to Interim Consolidated Financial Statements – February 28, 2022		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		27

Item 4.	Controls and Procedures		27

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings		28

Item 1A.	Risk Factors		28

Item 6.	Exhibits		29

SIGNATURES			30

	CEO Certification

	CFO Certification

	Section 906 Certification

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Interim Consolidated Financial Statements

Neogen Corporation and Subsidiaries

Consolidated Balance Sheets (unaudited)

(in thousands, except share and

per share amounts)


	February 28,			May 31,
	2022			2021
Assets
Current Assets
Cash and cash equivalents	$	42,879		$	75,602
Marketable securities		335,560			305,485
Accounts receivable, less allowance of $ 1,600 and $ 1,400 at February 28, 2022 and May 31, 2021, respectively		92,978			91,823
Inventories		113,395			100,701
Prepaid expenses and other current assets		24,821			17,840

Total Current Assets		609,633			591,451
Net Property and Equipment		104,699			100,453
Other Assets
Right of use assets		2,762			2,477
Goodwill		150,029			131,476
Other non-amortizable intangible assets		15,451			15,545
Amortizable intangible and other assets, net of accumulated amortization of $ 53,838 and $ 53,462 at February 28, 2022 and May 31, 2021, respectively		96,613			76,771
Other non-current assets		2,018			2,019

Total Assets	$	981,205		$	920,192

Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable	$	23,548		$	23,900
Accrued compensation		9,655			11,251
Income taxes		0			1,848
Other accruals		32,507			16,600

Total Current Liabilities		65,710			53,599
Deferred Income Taxes		21,196			21,917
Other Non-Current Liabilities		18,755			4,299

Total Liabilities		105,661			79,815
Commitments and Contingencies (note 10)
Equity
Preferred stock, $ 1.00 par value, 100,000 shares authorized, no ne issued and outstanding		—			—
Common stock, $ 0.16 par value, 120,000,000 shares authorized, 107,818,159 and 107,468,304 shares issued and outstanding at February 28, 2022 and May 31, 2021, respectively		17,251			17,195
Additional paid-in capital		307,780			294,953
Accumulated other comprehensive loss		( 22,439	)		( 11,375	)
Retained earnings		572,952			539,604

Total Stockholders’ Equity		875,544			840,377

Total Liabilities and Stockholders’ Equity	$	981,205		$	920,192

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Income (unaudited)

(in thousands, except per share amounts)


	Three Months Ended						Nine Months Ended
	February 28,						February 28,
	2022			2021			2022			2021
Revenues
Product revenues	$	101,566		$	92,816		$	311,701		$	273,288
Service revenues		26,678			23,893			75,365			67,746

Total Revenues		128,244			116,709			387,066			341,034
Cost of Revenues
Cost of product revenues		56,550			49,466			167,650			145,336
Cost of service revenues		14,282			13,394			41,402			38,333

Total Cost of Revenues		70,832			62,860			209,052			183,669

Gross Margin		57,412			53,849			178,014			157,365
Operating Expenses
Sales and marketing		21,477			18,693			63,220			52,938
General and administrative		24,997			15,146			60,985			38,343
Research and development		4,561			4,236			13,218			12,170

Total Operating Expenses		51,035			38,075			137,423			103,451

Operating Income		6,377			15,774			40,591			53,914
Other Income (Expense)
Interest income		314			294			741			1,571
Other expense		( 48	)		( 91	)		( 34	)		( 363	)

Total Other Income		266			203			707			1,208

Income Before Taxes		6,643			15,977			41,298			55,122
Provision for Income Taxes		1,200			2,600			7,950			10,000

Net Income	$	5,443		$	13,377		$	33,348		$	45,122

Net Income Per Share
Basic	$	0.05		$	0.13		$	0.31		$	0.42

Diluted	$	0.05		$	0.12		$	0.31		$	0.42

Weighted Average Shares Outstanding
Basic		107,818			106,826			107,648			106,264
Diluted		108,133			107,390			108,130			106,768

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Comprehensive Income (unaudited)

(in thousands)


	Three Months Ended						Nine Months Ended
	February 28,						February 28,
	2022			2021			2022			2021
Net income	$	5,443		$	13,377		$	33,348		$	45,122
Other comprehensive income (loss), net of tax:
foreign currency translations		2,789			360			( 9,482	)		5,419
Other comprehensive loss, net of tax:
unrealized loss on marketable securities		( 993	)		( 115	)		( 1,582	)		( 552	)

Total comprehensive income	$	7,239		$	13,622		$	22,284		$	49,989

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of

Equity (unaudited)

(in thousands)


							Accumulated
					Additional		Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Income (Loss)			Earnings		Total
Balance, June 1, 2021		107 ,468	$	17,195	$	294,953	$	( 11,375	)	$	539,604	$	840,377
Exercise of options and share-based compensation expense		6		1		1,838		—			—		1,839
Issuance of shares under employee stock purchase plan		19		3		896		—			—		899
Net income for the three months ended August 31, 2021		—		—		—		—			17,077		17,077
Other comprehensive loss for the three months ended August 31, 2021		—		—		—		( 4,829	)		—		( 4,829	)

Balance, August 31, 2021		107,493		17,199		297,687		( 16,204	)		556,681	$	855,363
Exercise of options and share-based compensation expense		275		44		7,272		—			—		7,316
Net income for the three months ended November 30, 2021		—		—		—		—			10,828		10,828
Other comprehensive loss for the three months ended November 30, 2021		—		—		—		( 8,031	)		—		( 8,031	)

Balance, November 30, 2021		107,768		17,243		304,959		( 24,235	)		567,509	$	865,476
Exercise of options and share-based compensation expense		26		4		1,848		—			—		1,852
Issuance of shares under employee stock purchase plan		24		4		973		—			—		977
Net income for the three months ended February 28, 2022		—		—		—		—			5,443		5,443
Other comprehensive income for the three months ended February 28, 2022		—		—		—		1,796			—		1,796

Balance, February 28, 2022		10 7,818		17,251		307,780		( 22,439	)		572,952	$	875,544


							Accumulated
					Additional		Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Income (Loss)			Earnings		Total
Balance, June 1, 2020		105,892	$	16,943	$	249,221	$	( 19,709	)	$	478,722	$	725,177
Exercise of options and share-based compensation expense		172		28		5,811		—			—		5,839
Issuance of shares under employee stock purchase plan		18		3		665		—			—		668
Net income for the three months ended August 31, 2020		—		—		—		—			15,860		15,860
Other comprehensive income for the three months ended August 31, 2020		—		—		—		4,002			—		4,002

Balance, August 31, 2020		106,082	$	16,974	$	255,697	$	( 15,707	)	$	494,582	$	751,546
Exercise of options and share-based compensation expense		406		64		9,279		—			—		9,343
Net income for the three months ended November 30, 2020		—		—		—		—			15,885		15,885
Other comprehensive income for the three months ended November 30, 2020		—		—		—		621			—		621

Balance, November 30, 2020		106,488		17,038		264,976		( 15,086	)		510,467		777,395
Exercise of options and share-based compensation expense		386		62		10,968		—			—		11,030
Issuance of shares under employee stock purchase plan		20		4		716							720
Issuance of shares for Megazyme acquisiton		128		20		4,896							4,916
Net income for the three months ended February 28, 2021		—		—		—		—			13,377		13,377
Other comprehensive income for the three months ended February 28, 2021		—		—		—		245			—		245

Balance, February 28, 2021		107,022		17,124		281,556		( 14,841	)		523,844		807,683

See notes to interim consolidated financial statements.

Table of Contents

Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows (unaudited)

(in thousands)


	Nine Months Ended
	February 28,
	2022			2021
Cash Flows From Operating Activities
Net Income	$	33,348		$	45,122
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization		17,833			15,107
Share-based compensation		5,045			4,773
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable		( 883	)		1,019
Inventories		( 11,956	)		3,328
Prepaid expenses and other current assets		( 3,824	)		( 1,908	)
Accounts payable, accruals and other changes		8,085			( 8,321	)

Net Cash From Operating Activities		47,648			59,120
Cash Flows For Investing Activities
Purchases of property, equipment and other non-current intangible assets		( 11,891	)		( 19,393	)
Proceeds from the sale of marketable securities		284,367			602,233
Purchases of marketable securities		( 314,442	)		( 604,694	)
Business acquisitions, net of cash acquired		( 38,164	)		( 52,000	)

Net Cash For Investing Activities		( 80,130	)		( 73,854	)
Cash Flows From Financing Activities
Exercise of stock options and issuance of employee stock purchase plan shares		7,842			22,801

Net Cash From Financing Activities		7,842			22,801
Effect of Foreign Exchange Rates on Cash		( 8,083	)		( 854	)

Net Increase (Decrease) In Cash and Cash Equivalents		( 32,723	)		7,213
Cash and Cash Equivalents, Beginning of Period		75,602			66,269

Cash and Cash Equivalents, End of Period	$	42,879		$	73,482

See notes to interim consolidated financial statements.

Table of Contents

NEOGEN CORPORATION AND SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. ACCOUNTING POLICIES

BASIS OF PRESENTATION AND CONSOLIDATION

The accompanying unaudited consolidated financial statements include the accounts of Neogen Corporation (“Neogen” or the “Company”) and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form

10-Q

and Article 10 of Regulation

S-X.

Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying unaudited consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for the three and nine month periods ended February 28, 2022 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2022. For more complete financial information, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form

10-K

for the fiscal year ended May 31, 2021.

Our functional currency is the U.S. dollar. We translate our

non-U.S.

operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our consolidated statement of income.

Share and per share amounts reflect the June 4, 2021

2-for-1

stock split as if it took place at the beginning of the periods presented.

Recently Adopted Accounting Standards

Income Tax Simplification

On June 1, 2021, the Company adopted

ASU 2019-12, Income

Taxes (Topic 740). This guidance provides amendments to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this guidance did not have a material impact on our consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

Reference Rate Reform

In March 2020, the FASB issued Update

2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in a new reference rate may be accounted for as a continuation of the existing contract. This guidance is effective upon issuance of the update and applies to contract modifications made through December 31, 2022. We will adopt this standard when LIBOR is discontinued and our lender begins using the new reference rate. We are evaluating the impact the new standard will have on our consolidated financial statements and related disclosures, but do not anticipate a material impact.

Table of Contents

Comprehensive Income

Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted

accounting principles, are excluded from net income and recognized directly as a component of equity. Accumulated other

comprehensive income (loss) consists of foreign currency translation adjustments and unrealized gains or losses on our marketable securities.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own

assumptions.

Leases

We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all our leases are classified as operating leases. Topic 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a

right-of-use

asset representing its right to use the underlying asset for the lease term.

Right-of-use

assets are recorded in other assets on our consolidated balance sheets. Current and

non-current

lease liabilities are recorded in other accruals within current liabilities and other

non-current

liabilities, respectively, on our consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease. The

right-of-use

assets were $ 2,762,000 and $ 2,477,000 at February 28, 2022 and May 31, 2021, respectively. The total current and

non-current

lease liabilities were $ 2,781,000 and $ 2,492,000 at February 28, 2022 and May 31, 2021, respectively.

ESTIMATES AND ASSUMPTIONS

The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Accounts Receivable Allowance

Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts.

Table of Contents

Inventory

The reserve for obsolete and slow-moving inventory is reviewed at least quarterly based on an analysis of the inventory, considering the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or net realizable value is adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants

not-to-compete

and patents. Customer-based intangibles are amortized on either an accelerated or straight-line basis, reflecting the pattern in which the economic benefits are consumed, while all other amortizable intangibles are amortized on a straight-line basis; intangibles are generally amortized over 5 to 25 years. We review the carrying amounts of goodwill and other

non-amortizable

intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is recorded to operations.

Long-Lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for

possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Equity Compensation Plans

Share options awarded to employees, restricted stock units (RSUs) and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for inputs such as interest rates, expected dividends, an estimate of award forfeitures, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized. For RSUs, we use the intrinsic value method to value the units.

To value equity awards, several recognized valuation models exist; none of these models can be singled out as being the best or most correct. The model applied by us can accommodate most of the specific features included in the options granted, which are the reason for their use. If different models were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on our equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Note 7.

Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are

determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

Table of Contents

2. CASH AND MARKETABLE SECURITIES

Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with

original maturities of 90 days or less. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and believes it is not exposed to significant credit risk regarding its cash and cash equivalents. Cash and cash equivalents were $ 42,879,000 and $ 75,602,000 at February 28, 2022 and May 31, 2021, respectively. The carrying value of these assets approximates fair value due to the short maturity of these instruments and is classified as Level 1 in the fair value hierarchy.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers at February 28, 2022. Changes in market value are monitored and recorded on a monthly basis; in the event of a downgrade in credit quality subsequent to purchase, the marketable securities investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable securities portfolio. These securities are classified as available for sale. The primary objective of management’s short-term investment activity is to preserve capital for the purpose of funding current operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within other income on the income statement. Adjustments in the fair value of these assets are recorded in other comprehensive income.

Marketable Securities as of February 28, 2022 and May 31, 2021 are listed below by classification and remaining maturities.


			February 28,		May 31,
(in thousands)	Maturity		2022		2021
Commercial Paper & Corporate Bonds		0 - 90 days		94,740		106,631
		91 - 180 days		85,373		78,727
		181 days - 1 year		57,310		87,590
		1 - 2 years		97,887		26,752
Certificates of Deposit		0 - 90 days		250		3,262
		91 - 180 days		—		1,260
		181 days - 1 year		—		1,263
		1 - 2 years		—		—

Total Marketable Securities			$	335,560	$	305,485

The components of marketable securities at February 28, 2022 are as follows:


	Amortized		Unrealized		Unrealized
(in thousands)	Cost		Gains		Losses			Fair Value
Commercial Paper & Corporate Bonds		337,159		7		( 1,856	)		335,310
Certificates of Deposit		250		—		—			250

Total Marketable Securities	$	337,409	$	7	$	( 1,856	)	$	335,560

Table of Contents

The components of marketable securities at May 31, 2021 are as follows:


	Amortized		Unrealized		Unrealized
(in thousands)	Cost		Gains		Losses			Fair Value
Commercial Paper & Corporate Bonds		299,524		209		( 33	)		299,700
Certificates of Deposit		5,755		30		—			5,785

Total Marketable Securities	$	305,279	$	239	$	( 33	)	$	305,485

3. INVENTORIES

Inventories are stated at the lower of cost, determined by the

first-in,

first-out

method, or net realizable value. The components of inventories follow:


	February 28,		May 31,
(in thousands)	2022		2021
Raw materials	$	54,747	$	47,588
Work-in-process		6,314		6,412
Finished and purchased goods		52,334		46,701

	$	113,395	$	100,701

4. REVENUE RECOGNITION

The Company determines the amount of revenue to be recognized through application of the following steps:

•

Identification of the contract with a customer;

•

Identification of the performance obligations in the contract;

•

Determination of the transaction price;

•

Allocation of the transaction price to the performance obligations in the contract; and

•

Recognition of revenue when, or as, the Company satisfies the performance obligations.

Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognize revenue at a point in time when all of our performance obligations under the terms of a contract are satisfied. Revenue is recognized upon transfer of control of promised products and services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The collectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.

Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method for incentives that are offered to individual customers, and the expected-value method for programs that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.

The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred

Table of Contents

and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense. Revenue is recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.

The Company derives revenue from two primary sources - product revenue and service revenue.

Product revenue consists of shipments of:

•

Diagnostic test kits, dehydrated culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

•

Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and

•

Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

•

Genomic identification and related interpretive bioinformatic services; and

•

Other commercial laboratory services.

Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.

Payment terms for products and services are generally 30 to 60 days.

Table of Contents

The following table presents disaggregated revenue by major product and service categories for the three and nine month periods ended February 28, 2022 and 2021:


	Three Months ended February 28,				Nine Months ended February 28,
(in thousands)	2022		2021		2022		2021
Food Safety
Natural Toxins, Allergens & Drug Residues	$	17,965	$	18,255	$	59,397	$	57,271
Bacterial & General Sanitation		11,288		10,335		34,709		31,502
Culture Media & Other		18,145		16,094		56,136		42,480
Rodenticides, Insecticides & Disinfectants		9,577		8,436		25,459		24,324
Genomics Services		5,781		5,304		16,909		14,566

	$	62,756	$	58,424	$	192,610	$	170,143
Animal Safety
Life Sciences	$	1,339	$	1,399	$	4,011	$	4,122
Veterinary Instruments & Disposables		17,047		12,494		47,956		34,843
Animal Care & Other		9,449		8,873		29,517		25,902
Rodenticides, Insecticides & Disinfectants		18,359		18,085		58,777		56,470
Genomics Services		19,294		17,434		54,195		49,554

	$	65,488	$	58,285	$	194,456	$	170,891

Total Revenues	$	128,244	$	116,709	$	387,066	$	341,034

5. NET INCOME PER SHARE

The calculation of net income per share follows:


	Three Months Ended				Nine Months Ended
	February 28,				February 28,
(in thousands, except per share amounts)	2022		2021		2022		2021
Numerator for basic and diluted net income per share:
Net income attributable to Neogen	$	5,443	$	13,377	$	33,348	$	45,122
Denominator for basic net income per share:
Weighted average shares		107,818		106,826		107,648		106,264
Effect of dilutive stock options and RSUs		315		564		482		504

Denominator for diluted net income per share		108,133		107,390		108,130		106,768
Net income attributable to Neogen per share:
Basic	$	0.05	$	0.13	$	0.31	$	0.42

Diluted	$	0.05	$	0.12	$	0.31	$	0.42

Table of Contents

6. SEGMENT INFORMATION AND GEOGRAPHIC DATA

We have two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Our international operations in the United Kingdom, Mexico, Brazil, China and India originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer our complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.

The accounting policies of each of the segments are the same as those described in Note 1.

Segment information follows:


					Corporate and
	Food		Animal		Eliminations
(in thousands)	Safety		Safety		(1)			Total
As of and for the three months ended February 28, 2022
Product revenues to external customers	$	55,372	$	46,194	$	—		$	101,566
Service revenues to external customers		7,384		19,294		—			26,678

Total revenues to external customers		62,756		65,488		—			128,244
Operating income (loss)		8,191		10,783		( 12,597	)		6,377
Total assets		302,605		298,854		379,746			981,205
As of and for the three months ended February 28, 2021
Product revenues to external customers	$	51,965	$	40,851	$	—		$	92,816
Service revenues to external customers		6,459		17,434		—			23,893

Total revenues to external customers		58,424		58,285		—			116,709
Operating income (loss)		7,911		11,657		( 3,794	)		15,774
Total assets		287,690		239,179		353,347			880,216

(1)

Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, current and deferred tax accounts and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions

Table of Contents


					Corporate and
	Food		Animal		Eliminations
(in thousands)	Safety		Safety		(1)			Total
As of and for the nine months ended February 28, 2022
Product revenues to external customers	$	171,439	$	140,261	$	—		$	311,700
Service revenues to external customers		21,171		54,195		—			75,366

Total revenues to external customers		192,610		194,456		—			387,066
Operating income (loss)		29,216		36,246		( 24,871	)		40,591
As of and for the nine months ended February 28, 2021
Product revenues to external customers	$	151,951	$	121,337	$	—		$	273,288
Service revenues to external customers		18,192		49,554		—			67,746

Total revenues to external customers		170,143		170,891		—			341,034
Operating income (loss)		24,834		36,068		( 6,988	)		53,914

(1) Includes elimination of intersegment transactions.

The following table presents the Company’s revenue disaggregated by geographic location:


	Three months ended				Nine months ended
	February 28,				February 28,
(in thousands)	2022		2021		2022		2021
Domestic	$	77,297	$	70,387	$	231,454	$	207,544
International		50,947		46,322		155,612		133,490

Total revenue		128,244		116,709		387,066		341,034

7. EQUITY COMPENSATION PLANS

Incentive and

non-qualified

options to purchase shares of common stock have been granted to directors, officers and employees of Neogen under the terms of the Company’s stock option plans. These options are granted at an exercise price of not less than the fair market value of the stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five or ten years . A summary of stock option activity during the nine months ended February 28, 2022 follows:


				Weighted-
				Average
(Options in thousands)	Shares			Exercise Price
Options outstanding June 1, 2021		2,957		$	30.38
Granted		393			40.93
Exercised		( 276	)		22.69
Forfeited		( 27	)		31.18

Options outstanding February 28, 2022		3,047		$	32.43

During the three and nine month periods ended February 28, 2022 and 2021, the Company recorded $ 1,607,000 and $ 1,581,000 and $ 5,045,000 and $ 4,773,000 , respectively, of compensation expense related to its share-based awards.

Table of Contents

The weighted-average fair value per share of stock options granted during the first nine months of fiscal years 2022 and 2021, estimated on the date of grant using the Black-Scholes option pricing model, was $ 9.54 and $ 7.71 , respectively. The fair value of stock options granted was estimated using the following weighted-average assumptions.


	FY 2022	FY 2021
Risk-free interest rate	0.4 %	0.2 %
Expected dividend yield	0.0 %	0.0 %
Expected stock price volatility	32.8 %	31.3 %
Expected option life	3.12 years	3.25 years

The company grants restricted stock units (RSUs) to directors, officers and employees under the terms of the 2018 Omnibus Incentive Plan, which vest ratably over three and five year periods. The current units are expensed straight-line over the remaining weighted-average period of 4.32 years. On February 28, 2022 there was $ 6,203,000 in unamortized compensation cost related to

non-vested

RSUs.


				Weighted-
				Average
(Options in thousands)	Shares			Fair Value
RSUs outstanding June 1, 2021		121		$	34.21
Granted		120			40.91
Released		( 25	)		34.24
Forfeited		( 4	)		35.61

RSUs outstanding February 28, 2022		212		$	37.98

The Company offers eligible employees the option to purchase common stock at a 5 % discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of either the 2011 or the 2021 Employee Stock Purchase Plan; the discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10 % of compensation.

8. BUSINESS COMBINATIONS

The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions discussed below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

On July 31, 2020, the Company acquired the U.S. (including territories) rights to Elanco’s StandGuard

Pour-on

for horn fly and lice control in beef cattle, and related assets. This product line fits in well with Neogen’s existing agricultural insecticide portfolio and organizational capabilities. Consideration for the purchase was $ 2,351,000 in cash, all paid at closing. The final purchase price allocation, based upon the fair value of these assets determined using the income approach, included inventory of $ 51,000 and intangible assets of $ 2,300,000 (with an estimated life of 15 years). This product line is manufactured at Neogen’s operation in Iowa; the sales are reported within the Animal Safety segment.

On December 30, 2020, the Company acquired all of the stock of Megazyme, Ltd, an Ireland-based company, and its wholly-owned subsidiaries, U.S.-based Megazyme, Inc. and Ireland-based Megazyme IP. Megazyme is a manufacturer and supplier of diagnostic assay kits and enzymes to measure dietary fiber, complex carbohydrates and enzymes in food and beverages as well as animal feeds. This acquisition has allowed Neogen to expand its commercial relationships across food, feed and beverage companies, and provide additional food quality diagnostic products to commercial labs and food science research institutions. Consideration for the purchase was net cash of $ 39.8 million paid at closing, $ 8.6 million of cash placed in escrow payable to the former owner in two installments in two and four years, $ 4.9 million of stock issued at closing, and up to $ 2.5 million of contingent consideration, payable in two installments over one year, based upon an excess net sales formula. The final purchase price allocation, based upon the fair value of

Table of Contents

these assets and liabilities determined using the income approach, included accounts receivable of $ 1,376,000 , inventory of $ 5,595,000 , net property, plant and equipment of $ 12,599,000 , prepayments of $ 69,000 , accounts payable of $ 4,000 , other current liabilities of $ 1,815,000 , contingent consideration accrual of $ 2,458,000 ,

non-current

liabilities of $ 319,000 ,

non-current

deferred tax liabilities of $ 3,306,000 , intangible assets of $ 22,945,000 (with an estimated life of

15 - 20

years) and the remainder to goodwill

(non-deductible

for tax purposes). These values are Level 3 fair value measurements. In February 2021, the former owner was paid $ 1,229,000 for the first installment of contingent consideration, based upon the achievement of sales targets. In January 2022, the former order was paid $ 1,120,000 for the second installment of contingent consideration, also based upon the achievement of sales targets, less a deduction of $ 120,000

related to a prior period tax adjustment. The Irish companies continue to operate from their current locations in Bray, Ireland, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation. The company’s U.S. business is managed by our Lansing-based Food Safety team.

On September 17, 2021, the Company acquired the stock of CAPInnoVet, Inc., a companion animal health business that provides pet medications to the veterinary market. This acquisition provides entry into the retail parasiticide market and enhances the Company’s presence in companion animal markets. Consideration for the purchase was net cash of $ 17.9 million paid at closing, including $ 150,000 of cash placed in escrow payable to the former owners in twelve months. There is also the potential for performance milestone payments to the former owners of up to $ 6.5 million and the Company could incur up to $ 14.5 million in future royalty payments. The preliminary purchase allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $ 308,000 , inventory of $ 482,000 , prepayments of $ 296,000 , accounts payable of $ 120,000 , other current liabilities of $ 132,000 ,

non-current

liabilities of $ 13.9 million, intangible assets of $ 21.0 million (with an estimated life of

15 - 20

years) and the remainder to goodwill

(non-deductible

for tax purposes). These values are Level 3 fair value measurements. The business is operated from our location in Lexington, KY, reporting within the Animal Safety segment.

On November 30, 2021, the Company acquired the stock of Delf (U.K.) Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products, and Abbott Analytical Ltd., a related service provider. This acquisition will expand the Company’s line of dairy hygiene products and will enhance our cleaner and disinfectant product portfolio. Consideration for the purchase was net cash of $ 9.5 million paid at closing, including $ 722,000 of cash placed in escrow payable to the former owner in one year. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $ 1,059,000 , inventory of $ 891,000 , net property, plant and equipment of $ 152,000 , prepayments of $ 31,000 , accounts payable of $ 497,000 , other current liabilities of $ 378,000 ,

non-current

deferred tax liabilities of $ 669,000 , intangible assets of $ 2.6 million (with an estimated life of

10 - 15

years) and the remainder to goodwill

(non-deductible

for tax purposes). These values are Level 3 fair value measurements. The companies continue to operate from their current location in Liverpool, England, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation.

On December 9, 2021, the Company acquired the stock of Genetic Veterinary Sciences, Inc., a companion animal genetic testing business providing genetic information for dogs, cats and birds to animal owners, breeders and veterinarians. This acquisition will further expand the Company’s presence in the companion animal market. Consideration for the purchase was $ 11.4 million in net cash. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $ 38,000 , inventory of $ 523,000 , net property, plant and equipment of $ 400,000 , prepayments of $ 55,000 , accounts payable of $ 297,000 , unearned revenue of $ 1.6 million, other current liabilities of $ 287,000 , intangible assets of $ 5.0 million (with an estimated life of

10 - 15

years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The business

operated from its current location in Spokane, Washington, reporting within the Animal Safety segment.

On December 13, 2021, the Company entered into a series of agreements to combine with 3M’s Food Safety business in a Reverse Morris Trust transaction, which is expected to close in the first quarter of our next fiscal year. Please refer to Forms

8-K,

dated December 14 and 15, 2021, Forms 425, dated December 14 and 15, 2021 and March 11, 2022, and

orm S-4, dated March 17, 2022, filed with the Securities and Exchange Commission for more information.

For each completed acquisition listed above, the revenues and net income were not considered material and were therefore not disclosed.

Table of Contents

9. LONG TERM DEBT

We have a financing agreement with a bank providing for a $ 15,000,000 unsecured revolving line of credit, which expires on November 30, 2023 . There were no advances against the line of credit during fiscal 2021 and there have been none thus far in fiscal 2022; there was no balance outstanding at February 28, 2022. Interest on any borrowings is at LIBOR plus 100 basis points (rate under the terms of the agreement was 1.24 % at February 28, 2022). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at February 28, 2022.

10. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these annual costs of remediation, which have ranged from $ 38,000 to $ 131,000 per year over the past five years. The Company’s estimated remaining liability for these costs was $ 916,000 at both February 28, 2022 and May 31, 2021, measured on an undiscounted basis over an estimated period of 15 years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources (WDNR) and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. However, the Company has agreed to a pilot study in which chemical reagents are injected into the ground in an attempt to reduce

on-site

contamination and is currently working with its consultant to design the system. At this time, the outcome of the pilot study is unknown, but a change in the current remediation strategy, depending on the alternative selected, could result in an increase in future costs and ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded $ 300,000 as a current liability, and the remaining $ 616,000 is recorded in other

non-current

liabilities in the consolidated balance sheets.

On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities.

In addition to responding to the administrative subpoena, the Company is implementing additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures will further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to U.S. economic sanctions and export control laws. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a material impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to expense and recorded a reserve of $ 600,000

to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for this issue. The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form

10-Q.

For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing

COVID-19

pandemic on our business, global business disruption caused by the Russia invasion in Ukraine and related sanctions, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

In addition, any forward-looking statements represent management’s views only as of the day this Quarterly Report on Form

10-Q

was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

COVID-19

As we closely monitor the

COVID-19

pandemic, our top priority remains protecting the health and safety of our employees. While operations continue in our locations around the world, many of our

non-manufacturing

and distribution employees continue to work remotely and travel remains limited. Safety guidelines and procedures, including social distancing, mask wearing and enhanced cleaning, have been developed for

on-site

employees and these policies are regularly monitored and updated by our internal Emergency Response Team.

In the first nine months of fiscal 2022,

COVID-19,

including new strains of the virus such as Delta and Omicron, continued to impact our business operations and financial results. A number of our food safety diagnostic product lines have been negatively impacted due to decreased demand in many of our customers’ businesses around the world, particularly those serving restaurants, bars and other institutional food service markets. Many of our markets across the world are recovering, but the pandemic has continued to adversely impact our customers and ultimately, our revenues. We have also experienced supply chain difficulties including vendor disruptions, border closures, shipping issues and significantly increased shipping costs; labor shortages and higher labor costs, as we have had to use staffing agencies and increase our base pay in many areas of the company to fill open positions; and restricted travel, which hinders our ability to connect with customers. During the current fiscal year, we have incurred less expense for travel, meals, trade shows and some other customer-facing marketing activities; some of these activities have resumed but have not yet returned to

pre-pandemic

levels. Higher spend on shipping and labor are offsetting these savings.

Overall, the impact

of COVID-19 remains

uncertain and ultimately depends on the length and severity of the pandemic, inclusive of the introduction of new strains of the virus; the federal, state, and local government actions taken in response; vaccination rates and effectiveness; the impact of vaccination requirements; and the macroeconomic environment. We will continue to evaluate the nature and extent to

which COVID-19 will

impact our business, supply chain, including labor availability and attrition, consolidated results of operations, financial condition, and liquidity; we expect it to impact us through at least the end of our current fiscal year.

Table of Contents

Executive Overview


	Three Months ended February 28,									Nine Months ended February 28,
(in thousands)	2022			2021			%			2022			2021			%
Consolidated
Revenues	$	128,244		$	116,709			10	%	$	387,066		$	341,034			13	%
Organic Sales Growth								6	%								10	%
Food Safety
Revenues	$	62,756		$	58,424			7	%	$	192,610		$	170,143			13	%
Organic Sales Growth								4	%								8	%
Animal Safety
Revenues	$	65,488		$	58,285			12	%	$	194,456		$	170,891			14	%
Organic Sales Growth								9	%								12	%
% of International Sales		40	%		40	%					40	%		39	%
Effective Tax Rate		18.1	%		16.3	%					19.3	%		18.1	%
Net Income	$	5,443		$	13,377			-59	%	$	33,348		$	45,122			-26	%
Per Diluted Share	$	0.05		$	0.12					$	0.31		$	0.42
Cash from Operations										$	47,648		$	59,120

•

Food Safety organic sales exclude revenues from the acquisitions of Megazyme (December 2020) and Delf/Abbott Analytical (November 2021).

•

Animal Safety organic sales exclude revenues from the acquisitions of StandGuard (July 2020), CAPInnoVet (September 2021) and Genetic Veterinary Sciences (December 2021).

•

Net income decreased by $9.3 million and $10.6 million in the second and third quarters, respectively, of the current fiscal year primarily due to legal and consulting expenses for due diligence related to our recently announced agreement to combine with 3M’s Food Safety business.

Table of Contents

International sales rose 10% in the third quarter of fiscal 2022 and increased 17% year to date, each compared to the same respective periods in the prior year. Excluding international sales from the Megazyme and Delf/Abbott Analytical acquisitions, the increase was 5% in the third quarter and 10% for the year to date. Revenue changes, expressed in percentages, for the three and nine month periods of fiscal 2022 compared to the same respective periods in the prior year are as follows for each of our international locations:


	Three Months Ended						Nine Months Ended
	February 28, 2022						February 28, 2022
	Revenue			Revenue			Revenue			Revenue
	% Inc (Dec)			% Inc (Dec)			% Inc (Dec)			% Inc (Dec)
	USD			Local Currency			USD			Local Currency
U.K. Operations (including Neogen Italia)		16	%		18	%		14	%		10	%
Brazil Operations		(2	)%		0	%		(8	)%		(8	)%
Neogen Latinoamerica		1	%		4	%		12	%		8	%
Neogen Argentina		18	%		44	%		25	%		59	%
Neogen Uruguay		22	%		27	%		8	%		11	%
Neogen Chile		13	%		28	%		40	%		46	%
Neogen China		(17	)%		(19	)%		13	%		9	%
Neogen India		53	%		57	%		19	%		20	%
Neogen Canada		10	%		10	%		38	%		33	%
Neogen Australasia		20	%		29	%		32	%		32	%

Currency translations decreased comparative revenues by approximately $891,000 in the third quarter of fiscal 2022, due to currencies in several countries, including Australia, Argentina, the U.K., Mexico and Brazil, weakening relative to the U.S. dollar. For the year to date, comparative revenues were $2.4 million higher due to increased strength of the British pound and Mexican peso relative to the U.S. dollar in the first half of the fiscal year. Combined revenues at our U.K. operations increased 16% in the third quarter, with growth from strong cleaner and disinfectant sales into the U.K. and Asia and new culture media business with commercial laboratories in the U.K. that have adopted our recently launched One Broth One Plate workflow. For the nine month period, revenues at our U.K. operations increased 14%.

Sales in Brazil decreased 2% in this year’s third quarter; the Company is discontinuing sales of lower gross margin dairy drug residue test kits which further contributed to an unfavorable comparison against the prior year. For the nine month period, sales at our Brazilian operations were down 8%, due to the previously mentioned decrease in dairy drug residue test kit sales and a large insecticide shipment that occurred in the first quarter of the prior year. Neogen Latinoamerica sales rose 1% for the third quarter; 10% growth in Food Safety products was offset by a decrease in sales of rodent control products to a large customer, due to the timing of shipments. For the year to date, sales increased 12%, primarily due to increases in natural toxins test kits, environmental sanitation products, culture media and biosecurity products. Sales at Neogen China decreased 17% for the three month period as China’s “Zero COVID” strategy created lockdowns and restricted travel, which limited our ability to record sales. For the nine month period, sales in China increased 13% from new sales of Megazyme products and growth in genomics services, partially offset by a decrease in sales of biosecurity products in the third quarter. The Neogen Australasia location benefitted from increased genomics business with customers in the beef and sheep markets.

Service revenue, which includes genomics testing and other laboratory services, was $26.7 million in the third quarter of fiscal 2022, an increase of 12% over the prior year third quarter revenues of $23.9 million. For the nine month period, service revenue was $75.4 million, an increase of 11% over prior year revenues of $67.7 million. The growth for both the quarter and year to date periods was led by increases in revenues at our international genomics operations and domestic growth in our Food Safety lab services; revenues at our domestic genomics operation were reduced by lower volumes of companion animal samples, the result of a difficult comparison due to large increases in the prior year.

Table of Contents

Revenues


	Three Months Ended February 28,
	Three Months Ended February 28,				Increase/
(in thousands)	2022		2021		(Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	17,965	$	18,255	$	(290	)		(2	)%
Bacterial & General Sanitation		11,288		10,335		953			9	%
Culture Media & Other		18,145		16,094		2,051			13	%
Rodenticides, Insecticides & Disinfectants		9,577		8,436		1,141			14	%
Genomics Services		5,781		5,304		477			9	%

	$	62,756	$	58,424	$	4,332			7	%
Animal Safety
Life Sciences	$	1,339	$	1,399	$	(60	)		(4	)%
Veterinary Instruments & Disposables		17,047		12,494		4,553			36	%
Animal Care & Other		9,449		8,873		576			6	%
Rodenticides, Insecticides & Disinfectants		18,359		18,085		274			2	%
Genomics Services		19,294		17,434		1,860			11	%

	$	65,488	$	58,285	$	7,203			12	%

Total Revenues	$	128,244	$	116,709	$	11,535			10	%


	Nine Months Ended February 28,
	Nine Months Ended February 28,				Increase/
(in thousands)	2022		2021		(Decrease)			%
Food Safety
Natural Toxins, Allergens & Drug Residues	$	59,397	$	57,271	$	2,126			4	%
Bacterial & General Sanitation		34,709		31,502		3,207			10	%
Culture Media & Other		56,136		42,480		13,656			32	%
Rodenticides, Insecticides & Disinfectants		25,459		24,324		1,135			5	%
Genomics Services		16,909		14,566		2,343			16	%

	$	192,610	$	170,143	$	22,467			13	%
Animal Safety
Life Sciences	$	4,011	$	4,122	$	(111	)		(3	)%
Veterinary Instruments & Disposables		47,956		34,843		13,113			38	%
Animal Care & Other		29,517		25,902		3,615			14	%
Rodenticides, Insecticides & Disinfectants		58,777		56,470		2,307			4	%
Genomics Services		54,195		49,554		4,641			9	%

	$	194,456	$	170,891	$	23,565			14	%

Total Revenues	$	387,066	$	341,034	$	46,032			13	%

Table of Contents

Food Safety

Natural Toxins, Allergens

& Drug Residues –

Sales in this category decreased 2% for the three month period and increased 4% for the nine month period ended February 28, 2022, respectively, compared to the same periods in the prior year. In the third quarter, a 12% increase in sales of allergen test kits was offset by a 55% decline in sales of dairy drug residue test kits, as we are discontinuing sales of certain lower margin products; sales of natural toxins test kits decreased 1%. For the year to date, sales of allergen test kits rose 11% and natural toxins test kits sales increased 5%, partially offset by a 33% decline in the drug residue product line, as compared to the same period in the prior year.

Bacterial

& General Sanitation –

Revenues in this category increased 9% and 10% for the third quarter and for the year to date, compared to the same periods in the prior year. In the third quarter, sales of our AccuPoint

sanitation monitoring product line increased 16% aided by strong sales of our new reader. Sales of our Listeria Right Now

™

product continued to gain market share with an increase of 13%, while sales of products to detect spoilage organisms in processed foods increased 4%.

Culture Media

& Other –

Sales in this category increased 13% in the quarter ended February 28, 2022 compared to the third quarter in the prior year; for the nine month period, sales increased 32%. Excluding sales from the December 2020 acquisition of Megazyme, which are reported in this category, sales increased 7% and 14% for the three and nine month periods, respectively. This category includes sales of veterinary instruments and other veterinary products at some of our international locations; these sales increased significantly over the prior year due to recovering markets and expanded market share. Sales of Neogen Culture Media products increased 11% in the third quarter as our new workflow, One Broth One Plate, continued to drive increased sales to commercial labs in the U.K. For the nine month period, Neogen Culture Media sales increased 18%, due to new business in the U.K. generated from our One Broth One Plate workflow; we also recorded a large domestic sale to a vaccine manufacturer in the first quarter of the current fiscal year.

Rodenticides, Insecticides

& Disinfectants –

Revenues in this category increased 14% in the third quarter of fiscal 2022 compared to the same period a year ago, primarily due to the continued strength in sales of cleaners and disinfectants to Asia resulting from the African swine fever outbreak in that region increasing demand, and higher sales to a U.K.-based toll manufacturer. For the year to date, sales increased 5%.

Genomics Services –

Sales of genomics services sold through our international Food Safety operations increased 9% and 16% for the three and nine month periods ended February 28, 2022, respectively. The increase in the third quarter resulted from overall strength at our labs in the U.K and Brazil as improved economic conditions in several markets have led to increased testing; our lab in China also contributed to the growth for the year to date period.

Animal Safety

Life Sciences –

Sales in this category decreased 4% in the third quarter, compared to the same period in the prior year; for the year to date, the decrease in this product line was 3%. The decline in both periods was primarily due to the loss of hair testing business with a large U.S. commercial laboratory that moved to a different testing platform and a decrease in workplace drug testing.

Veterinary Instruments

& Disposables –

Revenues in this category increased 36% for the three month period ended February 28, 2022, led by a large increase in sales of veterinary instruments, including needles and syringes, resulting from recently won private label business; revenues increased 38% for the year to date.

Animal Care

& Other –

Sales of these products increased 6% and 14% in the three and nine month periods ended February 28, 2022, respectively; excluding the contribution of parasiticides from the September acquisition of CAPInnoVet, revenues in this category increased 1% in the third quarter and 11% year to date. For both periods, the growth in our vitamin injectables and antibiotics product lines were partially offset by a decline in sales of dairy supplies due to the June 2020 termination of an agreement under which we distributed these types of products for a large manufacturer of dairy equipment.

Rodenticides, Insecticides

& Disinfectants –

Revenues in this category increased 2% for the three month period ended February 28, 2022. Insecticide sales rose 11% in the quarter, led by strong demand in the farm and home channels, and cleaners and disinfectants sales increased 2%. These increases were somewhat offset by a 5% decrease in rodenticide sales due to a difficult comparison resulting from strong sales in the prior year. Sales in this product category for the year to date period increased 4%, as compared to a year ago, for the same reasons.

Table of Contents

Genomics Services –

Sales in this category increased 11% and 9% in the third quarter and the year to date period, each compared to the prior year. The growth in both periods was led by increases in beef and sheep testing in Australia, due to improved market conditions and higher sample volumes from domestic dairy and beef cattle and poultry customers. Growth in both the three and nine month periods was partially offset by lower domestic companion animal revenues due to difficult prior year comparisons resulting from strong sales growth in those periods.

Gross Margin

Gross margin, expressed as a percentage of sales, was 44.8% in the third quarter of fiscal 2022 compared to 46.1% in the same quarter a year ago. The decline in gross margin percentage is the result of a 260 basis point decline in gross margin percentage in the Animal Safety segment; Food Safety gross margins remained constant compared to those in last year’s third quarter, as a favorable product mix shift was offset by increased overhead costs. In the Animal Safety segment, the decline in gross margin percentage at the raw material line was the result of a mix shift resulting from lower sales of higher margin rodenticide products, due to a lessening of vole pressure across the domestic market, and a reduction in genomics service revenues in the domestic companion animal markets. Each of those product lines experienced significant growth in the prior year periods, resulting in difficult comparisons in the current year. Within each segment, higher raw material and freight costs, which resulted from continued supply chain disruptions and ongoing issues related to

COVID-19

and its variants across most of our markets, put downward pressure on gross margins. The Company has taken pricing actions where appropriate in response to these cost increases. For the year to date, gross margin was 46.0% compared to 46.1% in the prior year, for the same reasons listed above.

Operating Expenses

Operating expenses were $51.0 million in the third quarter, compared to $38.1 million in the same quarter of the prior year, an increase of $12.9 million, or 34%. Legal, consulting and other professional fees totaling $10.6 million were incurred in the third quarter in conjunction with due diligence and negotiation of terms for our proposed business combination with 3M’s Food Safety business, which was announced on December 14, 2021. Excluding costs related to the transaction, run rate operating expenses for the third quarter were $40.4 million, an increase of 6% compared to the prior year. For the nine month period ended February 28, 2022, operating expenses were $137.4 million, an increase of 33% compared to the prior year. Legal, consulting and other professional fees totaling $19.9 million have been incurred year to date in conjunction with due diligence and negotiation of terms for the proposed business combination with 3M’s Food Safety business. Excluding the costs related to the transaction, run rate operating expenses year to date were $117.5 million, an increase of 14% compared to the prior year.

Sales and marketing expenses increased $2.8 million, or 15%, in the third quarter, primarily due to increases in personnel related expenses, the result of higher sales volumes and headcount. Additionally, travel, trade shows and other customer facing activities have continued to increase, the result of the easing of certain

COVID-19

pandemic restrictions in a number of our markets. Shipping expenses increased 10% for the quarter and were up 19% for the year to date on increased volume and rates; for the year to date, sales and marketing expenses increased 19% compared to the same period last year.

General and administrative expense increased $9.9 million in the third quarter, primarily the result of $10.6 million in legal, consulting and other professional fees resulting from due diligence efforts and negotiation of terms relating to the proposed transaction with 3M referenced above. In the prior year third quarter, $2.3 million was incurred on strategic consulting, legal and other professional fees for an acquisition which we the Company was unsuccessful in completing. After adjusting for these acquisition expenses, third quarter run rate general and administrative expenses increased $1,532,000, or 12%. Year to date run rate general and administrative expenses rose $5.4 million, or 15%. For each comparative period, increases were the result of higher salaries and bonuses resulting from improved operating performance and additional senior management hires, amortization expenses from the Megazyme, CAPInnoVet and Delf (U.K.) acquisitions and higher depreciation and license fees relating to information technology infrastructure and software.

Research and development expense was $4.6 million in the third quarter, an increase of $325,000, or 8%, compared to the same period in the prior year. The increase was primarily the result of compensation and other personnel related increases and, for the three month period, incremental costs of personnel absorbed from the GVS acquisition in December 2021. For the year to date, research and development expenses increased 9% over the same period last year; the increases were the result of compensation and other personnel related increases, and the incremental costs of personnel absorbed from the Megazyme and GVS acquisitions. For each comparative period, these increases were somewhat offset by decreased outside service costs for new reader development, as these products were launched in the prior year.

Table of Contents

Operating Income

Operating income was $6.4 million in the third quarter of fiscal 2022, compared to $15.8 million in the same period of the prior year. Adjusting for $10.6 million in costs resulting from the proposed 3M transaction, operating income was $17.0 million for the third quarter. Year to date operating income was $40.6 million compared to $53.9 million in the prior year; excluding $19.9 million in

3M-related

costs, operating income was $60.5 million.. Expressed as a percentage of sales, operating income was 5% for the third quarter and 10.5% for the year to date, compared to 13.5% and 15.8%, respectively, for the same periods in the prior year. Adjusting for the costs resulting from the proposed 3M transaction, operating income was 13.2% for the third quarter and 15.6% for the year to date.

Other Income


	Three Months Ended						Nine Months Ended
	February 28,						February 28,
(dollars in thousands)	2022			2021			2022			2021
Interest income (net of expense)	$	314		$	294		$	741		$	1,571
Foreign currency transactions		(185	)		(118	)		(170	)		(374	)
Insurance settlement		—			—			—			309
Legal settlement		—			—			—			(300	)
LGS contingent consideration		—			111			(135	)		111
Other		137			(84	)		271			(109	)

Total Other Income	$	266		$	203		$	707		$	1,208

The decrease in interest income in the nine month period of fiscal 2022, compared to the same period a year ago was the result of lower yields on our marketable securities balances. Other income or expense resulting from foreign currency transactions was the result of changes in the value of foreign currencies relative to the U.S. dollar in countries in which we operate. In the second quarter of the current fiscal year, we recorded a charge of $135,000 for additional contingent consideration in the final payment to the former owner of Livestock Genomic Services.

Income Tax Expense

Income tax expense in the third quarter of fiscal 2022 was $1.2 million, an effective tax rate of 18.1%, compared to $2.6 million, an effective tax rate of 16.3%, in the same period of the prior year. For the year to date, income tax expense was $8.0 million, an effective rate of 19.3%, in fiscal 2022 and $10.0 million, an effective rate of 18.1%, in fiscal 2021. For each period, the primary difference between the statutory rate of 21% and the effective rates recorded is the benefit resulting from the exercise of stock options; due to lower exercises in the third quarter of the current fiscal year, this benefit was $33,000, compared to $1,083,000 in the third quarter of the prior year. For the year to date, the benefit was $907,000 in fiscal 2022 compared to $2,564,000 in fiscal 2021. Additionally, we incurred a $548,000 charge to expense in the first quarter of this fiscal year, due to the U.K. enacting a higher tax rate effective in April 2023. Since our deferred tax balances in the U.K. are expected to reverse in the future at the higher tax rate, we were required to revalue them when the new rate was passed.

Net Income

Net income was $5.4 million in the third quarter of fiscal 2022, compared to $13.4 million in the same period in the prior year. The decline in earnings for the year to date was the result of $10.6 million in legal, consulting and other professional fees from the intended transaction with 3M. Excluding those charges, net income rose 2% compared to the same period in the prior year. For the year to date, net income was $33.3 million, a decrease of 26% compared to $45.1 million in the prior year. The decline in earnings for year to date was the result of $19.9 million in legal, consulting and other professional fees from the intended transaction with 3M. Excluding those charges, net income rose 8% year to date compared to the same period in the prior year. Nine month net income in fiscal 2022 was also negatively impacted by a higher effective tax rate.

Table of Contents

Financial Condition and Liquidity

The overall cash, cash equivalents and marketable securities position of Neogen was $378.4 million at February 28, 2022, compared to $381.1 million at May 31, 2021. Approximately $47.6 million was generated from operations during the first nine months of fiscal 2022 and we spent $38.2 million on business acquisitions. Net cash proceeds of $7.8 million were realized from the exercise of stock options and issuance of shares under our Employee Stock Purchase Plan during the first nine months of fiscal 2022. We spent $11.9 million for property, equipment and other

non-current

assets in the first nine months of fiscal 2022.

Net accounts receivable balances were $93.0 million at February 28, 2022, an increase of $1.2 million, compared to $91.8 million at May 31, 2021. Days’ sales outstanding, a measurement of the time it takes to collect receivables, were 64 days at February 28, 2022, compared to 66 days at May 31, 2021 and 65 days at February 28, 2021. We have been carefully monitoring our customer receivables as the

COVID-19

pandemic has spread across our global markets; to date, we have not experienced an appreciable increase in bad debt write offs related to the pandemic.

Net inventory was $113.4 million at February 28, 2022, an increase of $12.7 million, compared to a May 31, 2021 balance of $100.7 million. The two acquisitions completed in the second quarter added approximately $2.0 million to our inventory balance. The higher inventory levels are reflective of the inflationary pressures on raw material costs. Additionally, we have been increasing inventory levels recently in an effort to reduce freight costs and prevent backorders, as shipments from vendors are taking longer and some suppliers are requiring higher minimum order levels due to their supply constraints.

Inflation and changing prices are not expected to have a material effect on operations, as management believes it will continue to be successful in offsetting increased input costs with price increases and/or cost efficiencies.

Management believes that our existing cash and marketable securities balances at February 28, 2022, along with available borrowings under our credit facility and cash expected to be generated from operations, will be sufficient to fund activities for the remainder of the current fiscal year. However, existing cash and borrowing capacity will be insufficient to meet cash requirements for our planned combination with the 3M Food Safety business, which is currently expected to close in the third quarter of calendar year 2022. The transaction will be funded by issuing common stock to 3M’s shareholders and borrowing approximately $1 billion in cash under a financing agreement with JPMorgan Chase.

Table of Contents

PART I – FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. Our primary interest rate risk is due to potential fluctuations of interest rates for short-term investments.

Foreign exchange risk exposure arises because we market and sell our products throughout the world. Revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. dollar. Our operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, euro, Mexican peso, Brazilian real, Chinese yuan, Australian dollar and to a lesser extent, the Indian rupee, Canadian dollar, Guatemalan quetzal, Argentine peso, Uruguayan peso and Chilean peso; there is also exposure to a change in exchange rate between the British pound sterling and the euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously invoiced amounts can be positively or negatively affected by changes in exchange rates in the course of collection.

Neogen has assets, liabilities and operations outside of the U.S., located in Scotland, England, Ireland, Italy, Brazil, Mexico, Guatemala, Argentina, Uruguay, Chile, China, India, Canada and Australia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Guatemalan quetzal, Argentine peso, Uruguayan peso, Chilean peso, Chinese yuan, Indian rupee, Canadian dollar and Australian dollar, respectively. Our investments in foreign subsidiaries are considered long-term. As discussed in ITEM 1A. RISK FACTORS of our Annual Report on

Form 10-K

for the year ended May 31, 2021, our financial condition and results of operations could be adversely affected by currency fluctuations.

The following table sets forth the potential loss in future earnings or fair values, resulting from hypothetical changes in relevant market rates or prices:


Risk Category	Hypothetical Change	February 28, 2022		Impact
(dollars in thousands)
Foreign Currency - Revenue	10% Decrease in exchange rates	$	15,561	Earnings
Foreign Currency - Hedges	10% Decrease in exchange rates		1,973	Fair Value

PART I – FINANCIAL INFORMATION

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of February 28, 2022 was carried out under the supervision and with the participation of the Company’s management, including the President & Chief Executive Officer and the Vice President & Chief Financial Officer (“the Certifying Officers”). Based on the evaluation, the Certifying Officers concluded that the Company’s disclosure controls and procedures are effective.

Changes in Internal Controls over Financial Reporting

No changes in our control over financial reporting were identified as having occurred during the quarter ended February 28, 2022 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

For a description of our material pending legal proceedings, see Note 10 “Commitments and Contingencies” of the Notes to consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated by reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors described in the section captioned “Part I, Item 1A, Risk Factors” in our Annual Report on Form

10-K

for the fiscal year ended May 31, 2021, except for the following risk factor, which has been added to reflect risks associated with current global conditions:

We are subject to risks relating to existing international operations and expansion into new geographical markets.

We focus on expanding sales globally as part of our overall growth strategy and expect sales from outside the United States to continue to represent a significant portion of our revenue. Neogen’s international operations are subject to general risks related to such operations, including:

•

political, social and economic instability and disruptions, including social unrest, geopolitical tensions, currency, inflation and interest rate uncertainties;

•

government export controls, economic sanctions, embargoes or trade restrictions;

•

the imposition of duties and tariffs and other trade barriers;

•

limitations on ownership and on repatriation or dividend of earnings;

•

transportation delays and interruptions;

•

labor unrest and current and changing regulatory environments;

•

increased compliance costs, including costs associated with disclosure requirements and related due diligence;

•

difficulties in staffing and managing multi-national operations;

•

limitations on Neogen’s ability to enforce legal rights and remedies;

•

access to or control of networks and confidential information due to local government controls and vulnerability of local networks to cyber risks; and

•

fluctuations in foreign currency exchange rates.

If Neogen is unable to successfully manage the risks associated with expanding our global business or adequately manage operational risks of our existing international operations, these risks could have a material adverse effect on our growth strategy into new geographical markets, our reputation, our business, results of operations, financial condition and cash flows. In addition, the impact of such risks may be outside of Neogen’s control and could decrease our ability to sell products internationally, which could adversely affect our business, financial condition, results of operations or cash flows. For example, as a result of the ongoing military conflict between Russia and Ukraine and resulting heightened economic sanctions from the United States and the international community, Neogen has discontinued sales into Russia. The United States and other countries have imposed significant sanctions and could impose even wider sanctions and take other actions should the conflict further escalate. While it is difficult to anticipate the effect the sanctions announced to date may have on Neogen, any further sanctions imposed or actions taken by the United States or other countries, including any expansion of sanctions beyond Russia, could affect the global price and availability of raw materials, reduce our sales and earnings or otherwise have an adverse effect on our business and results of operations.

Table of Contents

tem

6. Exhibits

(a) Exhibit Index

2.1	Agreement and Plan of Merger, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation, Neogen Corporation and Nova RMT Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

2.2	Separation and Distribution Agreement, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

2.3	Asset Purchase Agreement, by and between 3M Company and Neogen Corporation, dated as of December 13, 2021 (incorporated by reference to Exhibit 2.3 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).

3.1	Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on March 17, 2022).

10.1	Employee Matters Agreement, dated as of December 13, 2021, by and among Neogen Corporation, Garden SpinCo Corporation and 3M Company (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021) .

31.1	Certification of Principal Executive Officer

31.2	Certification of Principal Financial Officer

32	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION

(Registrant)

Dated: April 1, 2022

/s/ John E. Adent

John E. Adent

President & Chief Executive Officer

(Principal Executive Officer)

Dated: April 1, 2022

/s/ Steven J. Quinlan

Steven J. Quinlan

Vice President & Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)